Eikon Therapeutics (NASDAQ: EIKN) has announced FDA clearance of its Investigational New Drug (IND) application for EIK1006, a novel androgen receptor antagonist, paving the way for its first-in-human Phase 1/2 study in...
MedMira (TSXV: MIR) has announced that the FDA has granted Breakthrough Device Designation to its Multiplo Complete Syphilis (TP/nTP) Antibody Test. According to MedMira, unlike conventional laboratory-based testing...
Allarity Therapeutics (NASDAQ: ALLR) has confirmed expanded eligibility for its ongoing Phase 2 stenoparib trial in advanced ovarian cancer, opening the study to patients with primary platinum-refractory disease and...
Lexeo Therapeutics (NASDAQ: LXEO) has announced positive interim data from the ongoing HEROIC-PKP2 Phase 1/2 clinical trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). According to...
Helus Pharma (NASDAQ: HELP; Cboe CA: HELP) has announced positive topline results from APPROACH, its Phase 3 pivotal study evaluating HLP003 (deuterated psilocin), as an adjunctive treatment for adults with major...
Cardiff Oncology (NASDAQ: CRDF) has announced that the FDA has granted Fast Track designation to onvansertib in combination with FOLFIRI/bevacizumab for the first-line treatment of adult patients with KRAS- or NRAS...
DBV Technologies (Euronext: DBV; ISIN: FR0010417345; NASDAQ: DBVT) has announced that three presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix...
Moleculin Biotech (NASDAQ: MBRX) has announced an Australian patent covering the preparation of preliposomal Annamycin lyophilizate, strengthening its intellectual property protection for the formulation technology...
Acute Care Alberta is leveraging top wound care products and technologies to treat the 21 soldiers who remain hospitalized in Alberta following the CFB Wainwright grass fire on October 17, 2026, including AVITA...
CytoDyn (OTCQB: CYDY) has announced that leronlimab will be evaluated in two new metastatic triple-negative breast cancer regimens within clinical research organization Quantum Leap Healthcare Collaborative’s...
Conexeu Sciences (NASDAQ: CNXU) has launched a human collagen program at its Vancouver research and development facility for regenerative aesthetics, starting with the production of its first pilot batch of human type I...
Modular Medical (NASDAQ: MODD) has announced the completion of an extensive market research study conducted with cardiometabolic patient insights company closely held Thrivable to evaluate perceptions of Modular...
Faeth Therapeutics (NASDAQ: FTH) has reported preliminary Phase 2 clinical results showing a confirmed objective response rate of 33% for its investigational PIKTOR treatment combined with paclitaxel in patients with...
Kyverna Therapeutics (NASDAQ: KYTX) has announced the publication of the primary analysis of KYSA-8, its registrational trial of miv-cel (mivocabtagene autoleucel, KYV-101) in patients with stiff person syndrome (SPS)...
In a recent LinkedIn post, Dr. Riam Shammaa, CEO of closely held Cell Technologies, and co-author of a recently published paper in Frontiers in Immunology, highlighted findings from an investigation into whether...
Azora Therapeutics (NASDAQ: AZR) has announced the formation of a five-member board of directors comprising individuals with extensive drug development experience, a track record of FDA approvals, public-company...
Opus Genetics (NASDAQ: IRD) has announced the completion of dosing in the higher-dose Cohort 2 of BIRD-1, its ongoing Phase 1/2 clinical trial evaluating OPGx-BEST1 in patients with BEST1-related retinal diseases...
Altimmune (NASDAQ: ALT) has announced that a late-breaking abstract featuring results from the RECLAIM Phase 2 trial evaluating pemvidutide in adults with moderate-to-severe alcohol use disorder (AUD) has been accepted...
Analysts for Raymond James and Lake Street Capital Markets say the CMS Final Rule released last evening is a win for Profound Medical (NASDAQ:PROF; TSX:PRN), confirming “very strong reimbursement” for the company’s...
Profound Medical (NASDAQ: PROF; TSX: PRN) has seen the first MRI-guided prostate cancer treatment performed using its TULSA-PRO system at the Mātai Medical Research Institute in Gisborne, New Zealand, following its...
Lucid Diagnostics (NASDAQ: LUCD), a subsidiary of PAVmed (Nasdaq: PAVM), has announced a peer-reviewed publication of findings from the largest real-world clinical experience of nonendoscopic esophageal precancer...
Pasithea Therapeutics (NASDAQ: KTTA) has announced that the FDA has cleared its Investigational New Drug (IND) application for a randomized, placebo-controlled Phase 2 clinical trial for PAS-004 in patients with NF1...